- Home
- ONCY vs FATE Comparison
ONCY vs FATE Comparison
Compare ONCY & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCY | FATE |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.5M | 125.6M |
| IPO Year | 2002 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ONCY | FATE |
|---|---|---|
| Price | $0.88 | $1.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $7.33 | $4.10 |
| AVG Volume (30 Days) | ★ 1.2M | 1.2M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,505.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $0.91 |
| 52 Week High | $1.51 | $1.94 |
Technical Indicators
Market Signals| Indicator | ONCY | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 46.34 |
| Support Level | $0.82 | $0.95 |
| Resistance Level | $1.14 | $1.30 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 10.17 | 14.89 |
Price Performance
Historical ComparisonAbout ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.